Voyager Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Voyager Therapeutics, Inc. (NASDAQ: VYGR) is a clinical-stage biotechnology company focused on leveraging human genetics to develop treatment options and potentially curative therapies for neurological diseases. The company's proprietary platform, TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA), is an adeno-associated virus (AAV) capsid discovery engine designed to identify novel capsids with enhanced blood-brain barrier penetration and cellular tropism. Voyager's pipeline targets severe central nervous system (CNS) disorders, including Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company advances its programs through a combination of wholly owned assets and strategic collaborations with major pharmaceutical partners, including Novartis, Alexion (AstraZeneca Rare Disease), and Neurocrine Biosciences.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing VY1706, a tau-silencing gene therapy candidate that utilizes a TRACER-derived AAV capsid to target tau production in the brain for the treatment of Alzheimer's disease.
Expected impact: Establishes clinical-stage validation for Voyager's wholly-owned neuro-gene therapy pipeline.
Developing a nonviral delivery platform designed to transport neurotherapeutics across the blood-brain barrier by targeting the ALPL receptor, enabling high brain penetration.
Expected impact: Expands Voyager's capabilities into nonviral delivery modalities, opening up new therapeutic targets and partnership opportunities.
Pausing lower-priority programs, such as the apolipoprotein E (APOE) gene therapy program, to redirect financial and operational resources toward more mature or higher-impact assets.
Expected impact: Extended the company's cash runway into 2028, ensuring sufficient liquidity to reach key clinical readouts.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating on multiple gene therapy programs, including Friedreich's ataxia (NBIB-'223) and GBA1 (targeting Parkinson's disease and Gaucher disease), leveraging Voyager's TRACER capsids.
Terms: Voyager is eligible for milestone-driven non-dilutive funding, including up to $35 million in near-term clinical/regulatory milestones for FA and GBA1 programs, and up to $2.4 billion in total potential development milestones.
Advancing TRACER capsid-based gene therapies for spinal muscular atrophy (SMA), Huntington's disease, and other undisclosed CNS targets.
Terms: Provides non-dilutive funding through upfront options, license fees, and potential future milestone payments.
Licensing novel TRACER capsids for an undisclosed rare neurological disease target.
Terms: Includes upfront payments, option exercise fees, and development/commercial milestones.